Literature DB >> 30233840

Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer.

Yanis Boumber1,2,3.   

Abstract

Entities:  

Year:  2018        PMID： 30233840      PMCID： PMC6129910          DOI： 10.21037/jtd.2018.07.120

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  20 in total

1.  Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials.

Authors:  Andrea Ardizzoni; Marcello Tiseo; Luca Boni
Journal:  Eur J Cancer       Date:  2014-06-26       Impact factor: 9.162

2.  PD-L1 expression in small cell neuroendocrine carcinomas.

Authors:  Anne M Schultheis; Andreas H Scheel; Luka Ozretić; Julie George; Roman K Thomas; Thorsten Hagemann; Thomas Zander; Jürgen Wolf; Reinhard Buettner
Journal:  Eur J Cancer       Date:  2015-01-09       Impact factor: 9.162

Review 3.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

4.  Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Authors:  Matthew D Hellmann; Margaret K Callahan; Mark M Awad; Emiliano Calvo; Paolo A Ascierto; Akin Atmaca; Naiyer A Rizvi; Fred R Hirsch; Giovanni Selvaggi; Joseph D Szustakowski; Ariella Sasson; Ryan Golhar; Patrik Vitazka; Han Chang; William J Geese; Scott J Antonia
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

Review 5.  Cancer immunotherapy using checkpoint blockade.

Authors:  Antoni Ribas; Jedd D Wolchok
Journal:  Science       Date:  2018-03-22       Impact factor: 47.728

6.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

7.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Authors:  Scott J Antonia; José A López-Martin; Johanna Bendell; Patrick A Ott; Matthew Taylor; Joseph Paul Eder; Dirk Jäger; M Catherine Pietanza; Dung T Le; Filippo de Braud; Michael A Morse; Paolo A Ascierto; Leora Horn; Asim Amin; Rathi N Pillai; Jeffry Evans; Ian Chau; Petri Bono; Akin Atmaca; Padmanee Sharma; Christopher T Harbison; Chen-Sheng Lin; Olaf Christensen; Emiliano Calvo
Journal:  Lancet Oncol       Date:  2016-06-04       Impact factor: 41.316

Review 8.  The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.

Authors:  Jedd D Wolchok; Yvonne Saenger
Journal:  Oncologist       Date:  2008

9.  Treatment decisions and survival for people with small-cell lung cancer.

Authors:  H A Powell; L J Tata; D R Baldwin; V A Potter; R A Stanley; A Khakwani; R B Hubbard
Journal:  Br J Cancer       Date:  2014-01-07       Impact factor: 7.640

Review 10.  Cancer immunotherapies targeting the PD-1 signaling pathway.

Authors:  Yoshiko Iwai; Junzo Hamanishi; Kenji Chamoto; Tasuku Honjo
Journal:  J Biomed Sci       Date:  2017-04-04       Impact factor: 8.410
View more
  18 in total

1.  Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers.

Authors:  Youming Lei; Kun Wang; Yinqiang Liu; Xuming Wang; Xudong Xiang; Xiangu Ning; Wanbao Ding; Jin Duan; Dingbiao Li; Wei Zhao; Yi Li; Fujun Zhang; Xiaoyu Luo; Yunfei Shi; Ying Wang; Depei Huang; Yuezong Bai; Hushan Zhang
Journal:  Front Immunol       Date:  2022-02-21       Impact factor: 7.561

2.  Characterizing the mutational landscape of MM and its precursor MGUS.

Authors:  Akanksha Farswan; Anubha Gupta; Lingaraja Jena; Vivek Ruhela; Gurvinder Kaur; Ritu Gupta
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

3.  Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.

Authors:  Lei Li; Xi Chen; Lu Hao; Qiuyan Chen; Haosheng Liu; Qing Zhou
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

4.  Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer.

Authors:  Stefanie Schatz; Markus Falk; Balázs Jóri; Hayat O Ramdani; Stefanie Schmidt; Eva-Maria Willing; Roopika Menon; Harry J M Groen; Linda Diehl; Matthias Kröger; Claas Wesseler; Frank Griesinger; Petra Hoffknecht; Markus Tiemann; Lukas C Heukamp
Journal:  Cancers (Basel)       Date:  2020-06-24       Impact factor: 6.639

5.  Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential.

Authors:  Jing Hu; Yu Wang; Yuan Zhang; Yanfei Yu; Hui Chen; Kuai Liu; Ming Yao; Kai Wang; Weiguang Gu; Tao Shou
Journal:  Cancer Med       Date:  2019-06-14       Impact factor: 4.452

Review 6.  Tumor mutation burden: from comprehensive mutational screening to the clinic.

Authors:  Francesca Galuppini; Carlo Alberto Dal Pozzo; Matteo Fassan; Raffaele Baffa; Jutta Deckert; Fotios Loupakis
Journal:  Cancer Cell Int       Date:  2019-08-07       Impact factor: 5.722

Review 7.  Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer.

Authors:  Caroline Lum; Muhammad Alamgeer
Journal:  Cancers (Basel)       Date:  2019-10-15       Impact factor: 6.639

8.  Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors.

Authors:  Dadasaheb Akolkar; Darshana Patil; Navin Srivastava; Revati Patil; Vineet Datta; Sachin Apurwa; Nitin Yashwante; Raja Dhasarathan; Rahul Gosavi; Jinumary John; Shabishta Khan; Ninad Jadhav; Priti Mene; Dhanashri Ahire; Sushant Pawar; Harshal Bodke; Subhraline Sahoo; Arun Nile; Dinesh Saindane; Harshal Darokar; Pradip Devhare; Ajay Srinivasan; Rajan Datar
Journal:  PLoS One       Date:  2021-02-08       Impact factor: 3.240

9.  Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas.

Authors:  Tyler J Wildes; Kyle A Dyson; Connor Francis; Brandon Wummer; Changlin Yang; Oleg Yegorov; David Shin; Adam Grippin; Bayli DiVita Dean; Rebecca Abraham; Christina Pham; Ginger Moore; Carmelle Kuizon; Duane A Mitchell; Catherine T Flores
Journal:  Clin Cancer Res       Date:  2020-08-11       Impact factor: 13.801

Review 10.  T-cell agonists in cancer immunotherapy.

Authors:  Yeonjoo Choi; Yaoyao Shi; Cara L Haymaker; Aung Naing; Gennaro Ciliberto; Joud Hajjar
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.